Trial Watch: Phase II and Phase III attrition rates 2011-2012

Nature Reviews Drug Discovery

Volumn 12, Issue 8, 2013, Pages 569-

  Arrowsmith, John ^a   Miller, Philip ^a  

^a THOMSON REUTERS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL NERVOUS SYSTEM DISEASE; DIABETES MELLITUS; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; MALIGNANT NEOPLASTIC DISEASE; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SURVIVAL RATE; THERAPEUTIC EQUIVALENCE; TREATMENT FAILURE; TREATMENT INDICATION; TREND STUDY;

CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; EARLY TERMINATION OF CLINICAL TRIALS; HUMANS; TREATMENT FAILURE;

EID: 84881296154     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4090     Document Type: Note

References (0)